Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Michael McCleerey has been named to the newly established position of Vice President, Marketing at Aerie, reporting directly to Thomas A. Mitro, President and Chief Operating Officer. Mr. McCleerey has more than 25 years of experience in the healthcare industry and ophthalmology-focused companies, with deep experience in marketing and strategic planning. He will be responsible for preparing for the commercial presence of Aerie’s lead product candidates. His appointment at Aerie is effective immediately.
Most recently, Mr. McCleerey served as Director Strategic Marketing, and previously, Director of Marketing at ISTA Pharmaceuticals. In these capacities, he was an instrumental member of the leadership team under which ISTA grew into the third largest branded prescription eye care business in the United States. During his tenure at ISTA, three of the company’s four products were number one in their markets, and their net sales more than tripled. Prior to joining ISTA, Mr. McCleerey held senior marketing positions, including Senior Product Manager, at Allergan, Inc., where he played a key role in the successful launch of Acular LS®. Mr. McCleerey received his B.A. degree in business administration and management from California State University at Fullerton and his M.B.A. degree from Pepperdine University.
“Aerie’s continued progress in its lead development programs, including the recent reporting of positive results from our Phase 2b study of Roclatan™, brings us closer to becoming a commercial-stage company. In light of this, we are pleased to announce the addition of Mike McCleerey to manage our marketing programs,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. “Mike and many of Aerie’s leaders have had strong track records of success in their previous roles at ISTA and Allergan, and we are excited to effectively reassemble a world-class team in ophthalmology.”
“I am very excited to join Aerie at this important time in its development, as the Company continues to advance its lead programs and nears commencement of registration studies of RhopressaTM for patients with glaucoma,” said Mr. McCleerey.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The Company is commencing two Phase 3 registration trials in the United States, named “Rocket 1” and “Rocket 2,” where the primary efficacy endpoint will be to demonstrate non-inferiority of intraocular pressure (IOP) lowering for RhopressaTM compared to timolol, along with a third Phase 3 registration safety-only trial, named “Rocket 3,” in Canada. The Company also recently completed a Phase 2b clinical trial where RoclatanTM met the primary efficacy endpoint, demonstrating the statistical superiority of Roclatan™ to each of its components.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; our expectations regarding the commercialization of our product candidates; our expectations related to the use of proceeds from our initial public offering; our estimates regarding anticipated capital requirements and our needs for additional financing; the potential advantages of our product candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Richard Rubino, 908-470-4320
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Angeli Kolhatkar, 212-213-0006
Justin Jackson, 212-213-0006